Kidney failure

No, taking drugs like Ozempic isn’t ‘cheating’ at weight loss or the ‘easy way out’

Retrieved on: 
Wednesday, April 10, 2024

Hundreds of thousands of people worldwide are taking drugs like Ozempic to lose weight.

Key Points: 
  • Hundreds of thousands of people worldwide are taking drugs like Ozempic to lose weight.
  • As demand for semaglutide increases, so are claims that taking it is “cheating” at weight loss or the “easy way out”.
  • We don’t tell people who need statin medication to treat high cholesterol or drugs to manage high blood pressure they’re cheating or taking the easy way out.

How does it work?

  • GLP-1 gets secreted by cells in your gut when it detects increased nutrient levels after eating.
  • GLP-1 receptor agonist (GLP-1RA) medications like Ozempic help the body’s own GLP-1 work better by mimicking and extending its action.
  • Read more:
    The rise of Ozempic: how surprise discoveries and lizard venom led to a new class of weight-loss drugs

What can users expect? What does the research say?

  • Higher doses of semaglutide are prescribed to treat obesity compared to type 2 diabetes management (up to 2.4mg versus 2.0mg weekly).
  • A large group of randomised controlled trials, called STEP trials, all tested weekly 2.4mg semaglutide injections versus different interventions or placebo drugs.
  • Trials lasting 1.3–2 years consistently found weekly 2.4 mg semaglutide injections led to 6–12% greater weight loss compared to placebo or alternative interventions.
  • Weight reduction due to semaglutide also leads to a reduction in systolic and diastolic blood pressure of about 4.8 mmHg and 2.5 mmHg respectively, a reduction in triglyceride levels (a type of blood fat) and improved physical function.
  • Another recent trial in adults with pre-existing heart disease and obesity, but without type 2 diabetes, found adults receiving weekly 2.4mg semaglutide injections had a 20% lower risk of specific cardiovascular events, including having a non-fatal heart attack, a stroke or dying from cardiovascular disease, after three years follow-up.

Who is eligible for semaglutide?

  • Australia’s regulator, the Therapeutic Goods Administration (TGA), has approved semaglutide, sold as Ozempic, for treating type 2 diabetes.
  • The TGA has approved Wegovy to treat obesity but it’s not currently available in Australia.

What else do you need to do during Ozempic treatment?

  • In addition to taking medication, people had brief lifestyle counselling sessions with dietitians or other health professionals every four weeks as a minimum in most trials.
  • The aim of these trials was to show the effect of adding the medication on top of other lifestyle counselling.


A review of obesity medication trials found people reported they needed less cognitive behaviour training to help them stick with the reduced energy intake. This is one aspect where drug treatment may make adherence a little easier. Not feeling as hungry and having environmental food cues “switched off” may mean less support is required for goal-setting, self-monitoring food intake and avoiding things that trigger eating.

But what are the side effects?

  • In on study these led to discontinuation of medication in 6% of people, but interestingly also in 3% of people taking placebos.
  • More severe side-effects included gallbladder disease, acute pancreatitis, hypoglycaemia, acute kidney disease and injection site reactions.
  • Here are some potential risks and benefits

    To reduce risk or severity of side-effects, medication doses are increased very slowly over months.

  • Health, Meat and Livestock Australia, and Greater Charitable Foundation.
  • She has consulted to SHINE Australia, Novo Nordisk, Quality Bakers, the Sax Institute, Dietitians Australia and the ABC.

Travere Therapeutics to Present Abstracts on FILSPARI® (sparsentan) in IgA Nephropathy at World Congress of Nephrology and the American Nephrology Nurses Association

Retrieved on: 
Wednesday, April 3, 2024

SAN DIEGO, April 03, 2024 (GLOBE NEWSWIRE) -- Travere Therapeutics, Inc., (Nasdaq: TVTX) today announced that the Company will present nine abstracts in rare kidney disease at the World Congress of Nephrology (WCN) in Buenos Aires, Argentina, on April 13-16, 2024, and the American Nephrology Nurses Association (ANNA) National Symposium in Orlando, Florida, on April 14-17, 2024.

Key Points: 
  • SAN DIEGO, April 03, 2024 (GLOBE NEWSWIRE) -- Travere Therapeutics, Inc., (Nasdaq: TVTX) today announced that the Company will present nine abstracts in rare kidney disease at the World Congress of Nephrology (WCN) in Buenos Aires, Argentina, on April 13-16, 2024, and the American Nephrology Nurses Association (ANNA) National Symposium in Orlando, Florida, on April 14-17, 2024.
  • At WCN, the Company will present subgroup analyses of the Phase 3 PROTECT Study of FILSPARI® (sparsentan) in IgA nephropathy (IgAN) showing the treatment effect across participants with different levels of baseline proteinuria.
  • At ANNA, the Company will present additional insights from the HONUS trial, including health-related quality of life (HRQoL) data and the humanistic burden experienced by patients with IgAN and focal segmental glomerulosclerosis (FSGS).
  • “The data we are presenting at WCN and ANNA reinforce the wealth of evidence supporting FILSPARI’s profile to become an effective foundational treatment replacing RAAS inhibition, with the potential to reduce the lifetime risk of kidney failure for patients with IgAN,” said Jula Inrig, M.D., chief medical officer of Travere Therapeutics.

Spotlighting Excellence: Keiretsu Forum Curates Premiere Investment Opportunities for the 2024 Angel Capital Association Innovation Funders Showcase

Retrieved on: 
Tuesday, April 2, 2024

PHILADELPHIA, April 02, 2024 (GLOBE NEWSWIRE) -- Keiretsu Forum Mid-Atlantic , South-East and Texas, leaders in angel investing, proudly announces its sponsorship of select pioneering companies at the annual Innovation Funders Spotlight during the 2024 Angel Capital Association (ACA) Summit.

Key Points: 
  • PHILADELPHIA, April 02, 2024 (GLOBE NEWSWIRE) -- Keiretsu Forum Mid-Atlantic , South-East and Texas, leaders in angel investing, proudly announces its sponsorship of select pioneering companies at the annual Innovation Funders Spotlight during the 2024 Angel Capital Association (ACA) Summit.
  • Showcase Companies and Keiretsu Forum's Involvement:
    Keiretsu Forum Mid-Atlantic, South-East, and Texas regions are sponsoring an impressive roster of enterprises, meticulously selected for their potential to transform their respective industries.
  • Keiretsu Forum has cultivated a legacy of investment that fosters innovation and industry advancement.
  • For additional information on the exemplary opportunities presented by Keiretsu Forum and attendance specifics for the ACA Summit's Innovation Funders Showcase, please contact Cindi Sutera at [email protected] or call at 610-613-2773.

How to keep your kidneys healthy – and how to spot when things are going wrong

Retrieved on: 
Tuesday, April 9, 2024

To keep your kidneys healthy there are several things you can do to help yourself.

Key Points: 
  • To keep your kidneys healthy there are several things you can do to help yourself.
  • Don’t let your kidneys dry out; make sure you drink a decent amount of fluid every day.
  • Drinking water is the best way to keep your kidneys hydrated, but any fluid such as tea or fruit-flavoured drinks are fine.
  • Smoking is bad for your kidneys, as it closes up the blood vessels in the kidneys and also increases blood pressure.

Orphan designation: Autologous CD34+ cells transduced with a lentiviral vector encoding galactosidase alpha Treatment of Fabry disease, 19/10/2020 Withdrawn

Retrieved on: 
Tuesday, April 9, 2024

Orphan designation: Autologous CD34+ cells transduced with a lentiviral vector encoding galactosidase alpha Treatment of Fabry disease, 19/10/2020 Withdrawn

Key Points: 


Orphan designation: Autologous CD34+ cells transduced with a lentiviral vector encoding galactosidase alpha Treatment of Fabry disease, 19/10/2020 Withdrawn

Orphan designation: Adeno-associated viral vector of serotype 5 containing the human alanine-glyoxylate-aminotransferase gene Treatment of primary hyperoxaluria type 1, 21/03/2012 Withdrawn

Retrieved on: 
Tuesday, April 9, 2024

Orphan designation: Adeno-associated viral vector of serotype 5 containing the human alanine-glyoxylate-aminotransferase gene Treatment of primary hyperoxaluria type 1, 21/03/2012 Withdrawn

Key Points: 


Orphan designation: Adeno-associated viral vector of serotype 5 containing the human alanine-glyoxylate-aminotransferase gene Treatment of primary hyperoxaluria type 1, 21/03/2012 Withdrawn

ProKidney Reports Full Year 2023 Financial Results and Recent Corporate Highlights

Retrieved on: 
Thursday, March 21, 2024

WINSTON-SALEM, N.C., March 21, 2024 (GLOBE NEWSWIRE) -- ProKidney Corp. (Nasdaq: PROK) (“ProKidney” or the “Company"), a leading late clinical-stage cellular therapeutics company focused on chronic kidney disease (CKD), today announced financial results for the year ended December 31, 2023.

Key Points: 
  • WINSTON-SALEM, N.C., March 21, 2024 (GLOBE NEWSWIRE) -- ProKidney Corp. (Nasdaq: PROK) (“ProKidney” or the “Company"), a leading late clinical-stage cellular therapeutics company focused on chronic kidney disease (CKD), today announced financial results for the year ended December 31, 2023.
  • In November, the Company announced Dr. Bruce Culleton assumed the role of the CEO and joined the ProKidney board of directors.
  • Dr. Culleton joined ProKidney in July 2023 as Executive Vice President of Clinical Development and Commercialization.
  • Mr. Periera-Kamath had previously joined ProKidney in July 2023 as Vice President of Business Development & Innovative Solutions.

American Kidney Fund Launches Phosphorus Management Education and Awareness Campaign

Retrieved on: 
Tuesday, March 19, 2024

ROCKVILLE, Md., March 19, 2024 (GLOBE NEWSWIRE) -- The American Kidney Fund (AKF) today announced a new patient-focused educational awareness campaign on managing high phosphorus, also known as hyperphosphatemia.

Key Points: 
  • ROCKVILLE, Md., March 19, 2024 (GLOBE NEWSWIRE) -- The American Kidney Fund (AKF) today announced a new patient-focused educational awareness campaign on managing high phosphorus, also known as hyperphosphatemia.
  • AKF’s phosphorus management education campaign will work to raise awareness among dialysis patients about why phosphorus levels matter, ways to manage phosphorus intake with low phosphorus foods and fluids, and information about existing and new phosphate lowering medications, including phosphate blockers.
  • The campaign will provide people with a host of resources, including a patient-facing education page on AKF’s website; a page on AKF’s nutrition website, Kidney Kitchen ®; downloadable guides on talking to your doctor about phosphorus and low phosphorus foods; and a patient-facing session on hyperphosphatemia management at Kidney Action Week 2024 .
  • We hope that this campaign provides much-needed information to patients and families and can make an impact on their disease management.”

Revolutionizing Chronic Kidney Disease Management on World Kidney Day

Retrieved on: 
Thursday, March 14, 2024

Toronto, March 14, 2024 (GLOBE NEWSWIRE) -- Today, as the world marks World Kidney Day, LifeLabs, in exclusive partnership with Klinrisk, proudly announces a groundbreaking advancement in chronic kidney disease (CKD) screening and management: the inclusion of the Klinrisk Score as a validated equation in the prestigious Kidney Disease: Improving Global Outcomes (KDIGO) Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease , which was released yesterday.

Key Points: 
  • Toronto, March 14, 2024 (GLOBE NEWSWIRE) -- Today, as the world marks World Kidney Day, LifeLabs, in exclusive partnership with Klinrisk, proudly announces a groundbreaking advancement in chronic kidney disease (CKD) screening and management: the inclusion of the Klinrisk Score as a validated equation in the prestigious Kidney Disease: Improving Global Outcomes (KDIGO) Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease , which was released yesterday.
  • They will provide an accurate assessment of kidney health for millions affected by this disease, which can, in turn, help guide treatments, medical decisions, or referrals to nephrologists.
  • Together with LifeLabs, Klinrisk is poised to transform CKD management and improve outcomes for the millions affected by this debilitating disease."
  • LifeLabs will promote the Klinrisk test throughout March to raise awareness about the importance of regular testing in managing kidney health.

Vertex Announces FDA Clearance of Investigational New Drug Application for VX-407 for the Treatment of Autosomal Dominant Polycystic Kidney Disease (ADPKD)

Retrieved on: 
Thursday, March 21, 2024

Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that the U.S. Food and Drug Administration (FDA) has cleared the Investigational New Drug Application (IND) for VX-407, an investigational first-in-class small molecule corrector that targets the underlying cause of autosomal dominant polycystic kidney disease (ADPKD) in patients with a subset of PKD1 genetic variants.

Key Points: 
  • Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that the U.S. Food and Drug Administration (FDA) has cleared the Investigational New Drug Application (IND) for VX-407, an investigational first-in-class small molecule corrector that targets the underlying cause of autosomal dominant polycystic kidney disease (ADPKD) in patients with a subset of PKD1 genetic variants.
  • ADPKD is the most common inherited kidney disease, with an estimated 250,000 people in the U.S. and Europe living with ADPKD; however, there are no treatments currently available that address the underlying causal biology of the disease.
  • ADPKD is a life-shortening genetic kidney disease characterized by the growth of numerous kidney-enlarging cysts that impair kidney function and can ultimately lead to kidney failure, requiring dialysis or kidney transplantation, and premature death.
  • The majority of ADPKD cases are caused by variants in the PKD1 gene, which encodes the polycystin 1 (PC1) protein.